Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VNDA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis NCT06836557 · Idiopathic Gastroparesis, Diabetic Gastroparesis Tradipitant | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 17 | Mar 30, 2026 | Registry ↗ |
| Oct 9, 2026 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) NCT04652882 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm Tasimelteon, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 43 | Sep 4, 2026 | Registry ↗ |
| Oct 6, 2026 | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute… NCT00254202 · Schizophrenia Iloperidone, Ziprasidone | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 593 | Sep 26, 2006 | Registry ↗ |
| Oct 1, 2026 | Safety and Tolerability of Open-Labeled Iloperidone in Adolescents NCT05648591 · Schizophrenia, Bipolar I Disorder Iloperidone | VNDA Vanda Pharmaceuticals | Phase 4 | Recruiting | 100 | Dec 31, 2028 | Registry ↗ |
| Sep 24, 2026 | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Dep… NCT06830044 · Major Depressive Disorder (MDD) Milsaperidone, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Recruiting | 500 | Mar 2028 | Registry ↗ |
| Sep 24, 2026 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastropare… NCT04028492 · Idiopathic Gastroparesis, Diabetic Gastroparesis Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 979 | Feb 21, 2025 | Registry ↗ |
| Sep 22, 2026 | Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic… NCT07362017 · Moderate-to-severe Chronic Plaque Psoriasis Ponesimod | VNDA Vanda Pharmaceuticals | Phase 3 | Recruiting | 300 | Aug 2028 | Registry ↗ |
| Aug 19, 2026 | Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient NCT07223632 · Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (… VCA-894A | VNDA Vanda Pharmaceuticals | Phase 1/2 | Active, not recruiting | 1 | Mar 2027 | Registry ↗ |
| Aug 18, 2026 | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Sev… NCT07686081 · Ulcerative Colitis (UC) Ponesimod, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Recruiting | 150 | Apr 2029 | Registry ↗ |
| Aug 17, 2026 | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety… NCT07221578 · Social Anxiety Disorder (SAD) VQW-765, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Active, not recruiting | 500 | Dec 2026 | Registry ↗ |
| Jun 5, 2026 | Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia NCT06953869 · Insomnia Disorder Tasimelteon Oral Suspension, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Recruiting | 420 | Nov 2027 | Registry ↗ |
| Apr 20, 2026 | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use NCT07446439 · Nausea and Vomiting, Obesity Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Recruiting | 280 | Dec 1, 2026 | Registry ↗ |
| Apr 16, 2026 | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion S… NCT06138613 · Motion Sickness Tradipitant | VNDA Vanda Pharmaceuticals | Phase 3 | Active, not recruiting | 705 | Sep 30, 2027 | Registry ↗ |
| Mar 27, 2026 | Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Sub… NCT05366855 · Generalized Pustular Psoriasis Double-blind 200 mg imsidolimab, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Terminated | 42 | Jul 12, 2024 | Registry ↗ |
| Mar 17, 2026 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With… NCT05352893 · Generalized Pustular Psoriasis 750 mg Imsidolimab, 300 mg Imsidolimab | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 45 | Aug 17, 2023 | Registry ↗ |
| Mar 16, 2026 | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignanci… NCT03838926 · Relapsed or Refractory Hematologic Malignancies Trichostatin A | VNDA Vanda Pharmaceuticals | Phase 1 | Recruiting | 42 | Dec 2027 | Registry ↗ |
| Feb 27, 2026 | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolle… NCT07090161 · Hypertension, Uncontrolled Hypertension iloperidone, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Recruiting | 240 | Oct 2026 | Registry ↗ |
| Feb 4, 2026 | Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis NCT07065773 · Onychomycosis of Toenail Trichostatin A | VNDA Vanda Pharmaceuticals | Phase 2 | Active, not recruiting | 50 | Sep 2026 | Registry ↗ |
| Jan 12, 2026 | Randomized Withdrawal Study in Patients With Schizophrenia NCT06961968 · Schizophrenia iloperidone, placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Recruiting | 400 | Nov 2027 | Registry ↗ |
| Nov 12, 2025 | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use NCT06804603 · Obesity Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 124 | Oct 6, 2025 | Registry ↗ |
| Sep 22, 2025 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participant… NCT04856930 · Hidradenitis Suppurativa Imsidolimab, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 149 | Jul 15, 2022 | Registry ↗ |
| Sep 22, 2025 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participant… NCT04856917 · Acne Vulgaris Imsidolimab, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 123 | Feb 1, 2022 | Registry ↗ |
| Sep 22, 2025 | A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneifor… NCT04697069 · Acneiform Eruptions Imsidolimab, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Terminated | 4 | Dec 13, 2021 | Registry ↗ |
| Sep 19, 2025 | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions NCT06494397 · Schizophrenia, Bipolar I Disorder VHX-896 and iloperidone, Iloperidone and VHX-896 | VNDA Vanda Pharmaceuticals | Phase 1 | Completed | 26 | Oct 24, 2024 | Registry ↗ |
| Sep 17, 2025 | An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treat… NCT07179055 · Dry Eye VSJ-110, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Recruiting | 160 | Sep 2026 | Registry ↗ |
| Sep 16, 2025 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participant… NCT04697056 · Ichthyosis Imsidolimab, placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Terminated | 5 | Nov 19, 2021 | Registry ↗ |
| Sep 16, 2025 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pust… NCT03619902 · Generalized Pustular Psoriasis Imsidolimab | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 8 | Jan 20, 2021 | Registry ↗ |
| Sep 15, 2025 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pus… NCT03633396 · Palmoplantar Pustulosis Imsidolimab, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 59 | Apr 23, 2021 | Registry ↗ |
| Sep 11, 2025 | Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History… NCT04622345 · Allergic Conjunctivitis VSJ-110, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 47 | May 22, 2021 | Registry ↗ |
| Aug 24, 2025 | Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis NCT04474990 · Gastroparesis, Diabetic Gastroparesis Tradipitant | VNDA Vanda Pharmaceuticals | — | Available | — | — | Registry ↗ |
| May 9, 2025 | Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Si… NCT03772340 · Motion Sickness Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 126 | Jun 6, 2019 | Registry ↗ |
| Apr 4, 2025 | Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Moti… NCT05903924 · Motion Sickness Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 316 | Apr 6, 2024 | Registry ↗ |
| Jan 31, 2025 | Food Effect Study of VHX-896 in Healthy Volunteers NCT06803290 · Healthy VHX-896 | VNDA Vanda Pharmaceuticals | Phase 1 | Completed | 24 | Dec 27, 2022 | Registry ↗ |
| Dec 11, 2024 | Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sic… NCT04327661 · Motion Sickness Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 366 | Apr 1, 2023 | Registry ↗ |
| Nov 22, 2024 | Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and… NCT06701396 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm Tasimelteon, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Recruiting | 60 | Jun 30, 2025 | Registry ↗ |
| Aug 6, 2024 | Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis NCT02970968 · Gastroparesis VLY-686 (Tradipitant), Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 152 | Nov 2018 | Registry ↗ |
| Jun 13, 2024 | Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis NCT02651714 · Atopic Dermatitis Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 168 | Aug 4, 2017 | Registry ↗ |
| Jun 11, 2024 | Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic De… NCT02004041 · Treatment-resistant Pruritus Associated With Atopic Dermati… VLY-686, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 69 | Feb 19, 2015 | Registry ↗ |
| May 14, 2024 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) NCT04140695 · Atopic Dermatitis Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Terminated | 87 | Oct 14, 2020 | Registry ↗ |
| May 13, 2024 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) NCT03568331 · Atopic Dermatitis Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 375 | Dec 27, 2019 | Registry ↗ |
| Apr 18, 2024 | Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes… NCT04819776 · Bipolar I Disorder Iloperidone, Iloperidone Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | Completed | 417 | Sep 7, 2022 | Registry ↗ |
| Apr 16, 2024 | Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in… NCT04849559 · Healthy Volunteer Tradipitant, Placebo | VNDA Vanda Pharmaceuticals | Phase 1/2 | Completed | 27 | Sep 24, 2021 | Registry ↗ |
| Apr 3, 2024 | Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals W… NCT01218789 · Non 24 Hour Sleep Wake Disorder tasimelteon | VNDA Vanda Pharmaceuticals | Phase 3 | Unknown | 140 | Dec 5, 2024 | Registry ↗ |
| Mar 22, 2024 | WGS Analysis of COVID-19 Positive Patients NCT04353401 · Coronavirus Infection, COVID-19 | VNDA Vanda Pharmaceuticals | — | Completed | 79 | Mar 9, 2022 | Registry ↗ |
| Mar 21, 2024 | Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in… NCT06323655 · Healthy Volunteers Tasimelteon, Active Control Placebo | VNDA Vanda Pharmaceuticals | Phase 1 | Completed | 48 | Aug 28, 2018 | Registry ↗ |
| Mar 21, 2024 | Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in H… NCT05572281 · Healthy Tasimelteon Oral Capsule, Tasimelteon Oral Suspension | VNDA Vanda Pharmaceuticals | Phase 1 | Completed | 36 | Jun 15, 2022 | Registry ↗ |
| Mar 21, 2024 | Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep… NCT05361707 · Autism Spectrum Disorder, Sleep Disorder Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | VNDA Vanda Pharmaceuticals | Phase 3 | Unknown | 100 | Jul 2025 | Registry ↗ |
| Mar 21, 2024 | A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis NCT05344365 · Parkinson Disease Psychosis Iloperidone | VNDA Vanda Pharmaceuticals | Phase 2 | Withdrawn | 0 | Nov 2023 | Registry ↗ |
| Mar 21, 2024 | Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents NCT02776215 · Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Di… tasimelteon | VNDA Vanda Pharmaceuticals | Phase 1 | Completed | 24 | Dec 20, 2017 | Registry ↗ |
| Mar 20, 2024 | Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety NCT04800237 · Performance Anxiety VQW-765, Placebo | VNDA Vanda Pharmaceuticals | Phase 2 | Completed | 230 | Aug 2, 2022 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:52 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances